Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978183 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
A Phase 2 study, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02978183 is a Phase 2 study that has completed, run by Noveome Biotherapeutics, formerly Stemnion. The registered enrollment target is 70 participants.
The verdict
NCT02978183, a Phase 2 study, has completed, sponsored by Noveome Biotherapeutics, formerly Stemnion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
Interventions
- BIOLOGICAL ST266
- DRUG Saline (0.9% NaCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02978183
The ClinicalTrials.gov registry entry for NCT02978183 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noveome Biotherapeutics, formerly Stemnion, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ST266 is the first listed.
NCT02978183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02978183 about?
NCT02978183 is a clinical study titled "Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis". The purpose of this study is to evaluate the efficacy of ST266 ophthalmic drops compared to placebo for the treatment of the signs and symptoms of allergic conjunctivitis.
What is the current status of trial NCT02978183?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-12. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02978183?
The interventions under investigation include: ST266 (BIOLOGICAL), Saline (0.9% NaCl) (DRUG).
Who is sponsoring clinical trial NCT02978183?
This trial is sponsored by Noveome Biotherapeutics, formerly Stemnion, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.